⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8958583 | 0.94 | — | — | |
| SCHEMBL506597 | 0.88 | — | — | |
| SCHEMBL9652183 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL10489308 | 0.82 | — | — | |
| SCHEMBL31256866 | 0.78 | CA2 (0.31) | — | |
| SCHEMBL4447889 | 0.78 | — | — | |
| SCHEMBL3828949 | 0.78 | — | — | |
| SCHEMBL10836473 | 0.78 | — | — | |
| SCHEMBL11777651 | 0.78 | — | — | |
| SCHEMBL14978793 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595481-B2 | Methods and compositions for neuroprotection | DISARM THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20230242909-A1 | METHODS AND COMPOSITIONS FOR NEUROPROTECTION | DISARM THERAPEUTICS, INC. | 2023-08-03 | — | — | US | claimed |
| CN-115176002-A | Methods and compositions for neuroprotection | 达萨玛治疗公司 | 2022-10-11 | — | — | CN | claimed |
| EP-4065714-A1 | METHODS AND COMPOSITIONS FOR NEUROPROTECTION | Disarm Therapeutics, Inc. (US) | 2022-10-05 | — | — | EP | claimed |
| WO-2021108602-A1 | METHODS AND COMPOSITIONS FOR NEUROPROTECTION | DISARM THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | WO | claimed |
| CN-112180007-A | Metabolics-based diagnostic marker for generalized pustular psoriasis and application thereof | 上海市皮肤病医院 | 2021-01-05 | — | — | CN | claimed |
| CN-111440796-A | Improved exon skipping compositions for the treatment of muscular dystrophy | 萨雷普塔医疗公司 | 2020-07-24 | — | — | CN | claimed |
| EP-3476474-B1 | REACTIVE SORBENT BASED ON ACTIVATED CLAY FOR DECONTAMINATING CHEMICAL WARFARE AGENT (CWA) AND DECONTAMINATION METHOD USING THE SAME | AGENCY DEFENSE DEV (KR) | 2020-06-03 | — | — | EP | claimed |
| CN-106460058-B | Modified cytosine polynucleotide oligomers and methods | 赛沛 | 2019-07-09 | — | — | CN | claimed |
| EP-3469084-A1 | HIGH SPECIFICITY GENOME EDITING USING CHEMICALLY MODIFIED GUIDE RNAS | Agilent Technologies, Inc. (US) | 2019-04-17 | — | — | EP | claimed |
| EP-0731835-A1 | ANTISENSE OLIGONUCLEOTIDES HAVING TUMORIGENICITY-INHIBITING ACTIVITY | HYBRIDON, Inc. (US) | 1996-09-18 | — | — | EP | claimed |
| EP-0711343-A1 | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION | HYBRIDON, Inc. (US) | 1996-05-15 | — | — | EP | claimed |
| WO-1995018137-A1 | IMPROVED PROCESS FOR THE PURIFICATION OF OLIGOMERS | GENTA INCORPORATED (US) | 1995-07-06 | — | — | WO | claimed |
| WO-1995015378-A1 | ANTISENSE OLIGONUCLEOTIDES HAVING TUMORIGENICITY-INHIBITING ACTIVITY | HYBRIDON, INC. (US) | 1995-06-08 | — | — | WO | claimed |
| WO-1995004142-A2 | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION | HYBRIDON, INC. (US) | 1995-02-09 | — | — | WO | claimed |
| EP-0450370-A1 | Branch migration of nucleotides | ENZO BIOCHEM, INC. (US) | 1991-10-09 | — | — | EP | claimed |
| EP-0431523-A2 | Modified nucleotide compounds | ENZO BIOCHEM, INC. (US) | 1991-06-12 | — | — | EP | claimed |
| EP-0022141-B2 | COMPOSITIONS AND METHODS FOR REDUCING HERBICIDAL INJURY | MONSANTO COMPANY (US) | 1987-12-02 | — | — | EP | claimed |
| EP-0022141-B1 | COMPOSITIONS AND METHODS FOR REDUCING HERBICIDAL INJURY | MONSANTO COMPANY (US) | 1983-06-08 | — | — | EP | claimed |
| US-3948925-A | INSECTICIDE, NEMATOCIDE, MITICIDE | ROUSSEL-UCLAF (FR) | 1976-04-06 | — | — | US | claimed |